-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, after a demonstration organized by the relevant departments of the State Council’s joint prevention and control mechanism, the new coronavirus inactivated vaccine of the Wuhan Institute of Biological Products of Sinopharm Group was approved for emergency use in people aged 3-17
From July 16, 2020, Wuhan Institute of Biological Products will carry out the "Phase III Clinical Trial of the New Coronary Inactivated Vaccine" in the UAE and other countries
The 3-17-year-old age group of the new crown vaccine of the Sinopharm Wuhan Institute of Biological Products has completed phase I/II clinical trials under the auspices of the Henan Provincial Center for Disease Control and Prevention
The 3-17-year-old age group of the new crown vaccine of the Sinopharm Wuhan Institute of Biological Products has completed phase I/II clinical trials under the auspices of the Henan Provincial Center for Disease Control and Prevention
With the continuous emergence of mutant strains of the new crown, the construction of the immune barrier also urgently needs to be further expanded.
On May 31, the second phase expansion project of the new crown inactivated vaccine of Sinopharm Wuhan Institute of Biological Products was officially completed and put into production.
New crown pneumonia
leave a message here